Abstract: Objective To discuss the clinical efficacy of thalidomide combined with paclitaxel plus cisplatin(TP) in treatment of advanced non-small cell lung cancer (NSCLC). Methods 84 elderly patients with advanced NSCLC which admission time is January 2013 to December 2014 were randomly divided into TP group and TP plus thalidomide respectively, Both groups contained 42 patients. The index of two groups to observe mainly contained clinical curative effect, tumor markers and side effects. Results The disease control rates of experimental group is high up to 85.71%, significantly higher than that in control group (χ²=5.143,P <0.05); the progress free survival and overall survival of experimental group were longer than that in control group (t=6.689, 2.754,P <0.05 ); The level of carcino-embryonic antigen (CEA), cancer antigen 125 (CA125) and cytokeratin-19-fragment (CYFRA21-1) of experimental group were 16.646, 15.125 and 16.428 (P <0.05). The incidence of nausea and vomiting of experimental group was 40.48%, obvious lower than that in control group which was 76.19%. Other adverse reactions such as lethargy, constipation and fatigue etc were significantly higher than control group. Both groups showed similar level of white blood cells, platelet and hemoglobin and the incidence of peripheral nerve toxicity(P >0.05). Conclusions Thalidomide combined with paclitaxel and cisplatin treatment helps to reduce the advanced non-small cell lung cancer serum tumor marker expression level, improve the clinical efficacy, but should prevent the side effects such as lethargy, constipation and fatigue etc.

Key words: advanced non-small cell lung cancer, thalidomide, paclitaxel, cisplatin, tumor markers